INTRODUCTION: The utility of [(18)F]FPBM [2-(2'-((dimethylamino)methyl)-4'-(3-[(18)F]-fluoropropoxy)phenylthio)benzenamine], a selective serotonin transporter (SERT) tracer, and [(18)F]AV-133 [(+)-2-Hydroxy-3-isobutyl-9-(3-fluoropropoxy)-10-methoxy-1,2,3,4,6,7-hexahydro-11bH-benzo[a]quinolizine], a selective vesicular monoamine transporter 2 (VMAT2) tracer, were tested in the 6-hydroxydopamine (6-OHDA) unilateral lesioned rat model. METHODS: Positron emission tomography (PET) imaging of three 6-OHDA unilateral lesioned male Sprague Dawley rats (Rats 1-3) were performed with [(18)F]FPBM and [(18)F]AV-133 to examine whether changes in SERT and VMAT2 binding, respectively, could be detected in the brain. The brains of the three rats were then removed and examined by in vitro autoradiography with [(18)F]FPBM and the dopamine transporter ligand, [(125)I]IPT [N-(3'-[(125)I]-iodopropen-2'-yl)-2-beta-carbomethoxy-3-beta-(4-chloro phenyl) tropane, for confirmation. Biodistribution of [(18)F]FPBM in a separate group of p-chloroamphetamine (PCA) treated rats were also performed. RESULTS: PET image analysis showed varying levels of SERT binding reduction (Rat 1=-11%, Rat 2=-4%, Rat 3=-43%; n=2) and a clear and definitive loss of VMAT2 binding (Rat 1=-87%, Rat 2=-72%, and Rat 3=-91%; n=1) in the left striatum when compared to the right (non-lesioned side) striatum. The results from PET imaging were corroborated with quantitative in vitro autoradiography. Rats treated with a selective serotonin toxin (p-chloroamphetamine) showed a significant reduction of [(18)F]FPBM uptake in the cortex and hypothalamus regions of the brain. CONCLUSION: The preliminary data suggest that [(18)F]FPBM and [(18)F]AV-133 may be useful for the examination of serotonergic and dopaminergic neuron integrity, respectively, in the living brain. (c) 2010 Elsevier Inc. All rights reserved.
INTRODUCTION: The utility of [(18)F]FPBM [2-(2'-((dimethylamino)methyl)-4'-(3-[(18)F]-fluoropropoxy)phenylthio)benzenamine], a selective serotonin transporter (SERT) tracer, and [(18)F]AV-133 [(+)-2-Hydroxy-3-isobutyl-9-(3-fluoropropoxy)-10-methoxy-1,2,3,4,6,7-hexahydro-11bH-benzo[a]quinolizine], a selective vesicular monoamine transporter 2 (VMAT2) tracer, were tested in the 6-hydroxydopamine (6-OHDA) unilateral lesioned rat model. METHODS: Positron emission tomography (PET) imaging of three 6-OHDA unilateral lesioned male Sprague Dawley rats (Rats 1-3) were performed with [(18)F]FPBM and [(18)F]AV-133 to examine whether changes in SERT and VMAT2 binding, respectively, could be detected in the brain. The brains of the three rats were then removed and examined by in vitro autoradiography with [(18)F]FPBM and the dopamine transporter ligand, [(125)I]IPT [N-(3'-[(125)I]-iodopropen-2'-yl)-2-beta-carbomethoxy-3-beta-(4-chloro phenyl) tropane, for confirmation. Biodistribution of [(18)F]FPBM in a separate group of p-chloroamphetamine (PCA) treated rats were also performed. RESULTS: PET image analysis showed varying levels of SERT binding reduction (Rat 1=-11%, Rat 2=-4%, Rat 3=-43%; n=2) and a clear and definitive loss of VMAT2 binding (Rat 1=-87%, Rat 2=-72%, and Rat 3=-91%; n=1) in the left striatum when compared to the right (non-lesioned side) striatum. The results from PET imaging were corroborated with quantitative in vitro autoradiography. Rats treated with a selective serotonin toxin (p-chloroamphetamine) showed a significant reduction of [(18)F]FPBM uptake in the cortex and hypothalamus regions of the brain. CONCLUSION: The preliminary data suggest that [(18)F]FPBM and [(18)F]AV-133 may be useful for the examination of serotonergic and dopaminergic neuron integrity, respectively, in the living brain. (c) 2010 Elsevier Inc. All rights reserved.
Authors: Mei-Ping Kung; Catherine Hou; Rajesh Goswami; Datta E Ponde; Michael R Kilbourn; Hank F Kung Journal: Nucl Med Biol Date: 2007-04 Impact factor: 2.408
Authors: Yoshifumi Saisho; Paul E Harris; Alexandra E Butler; Ryan Galasso; Tatyana Gurlo; Robert A Rizza; Peter C Butler Journal: J Mol Histol Date: 2008-09-13 Impact factor: 2.611
Authors: Julie L Wang; Ajit K Parhi; Shunichi Oya; Brian Lieberman; Mei-Ping Kung; Hank F Kung Journal: Nucl Med Biol Date: 2008-05 Impact factor: 2.408
Authors: Jeffrey H Meyer; Alan A Wilson; Sandra Sagrati; Doug Hussey; Anna Carella; William Z Potter; Nathalie Ginovart; Edgar P Spencer; Andy Cheok; Sylvain Houle Journal: Am J Psychiatry Date: 2004-05 Impact factor: 18.112
Authors: Samantha E Yohn; Laura Lopez-Cruz; Peter H Hutson; Merce Correa; John D Salamone Journal: Psychopharmacology (Berl) Date: 2015-12-23 Impact factor: 4.530
Authors: Elena Prieto; María Collantes; Mercedes Delgado; Carlos Juri; Luis García-García; Francisco Molinet; María E Fernández-Valle; Miguel A Pozo; Belén Gago; Josep M Martí-Climent; José A Obeso; Iván Peñuelas Journal: Eur J Nucl Med Mol Imaging Date: 2011-08-27 Impact factor: 9.236
Authors: Lin W Hung; Victor L Villemagne; Lesley Cheng; Nicki A Sherratt; Scott Ayton; Anthony R White; Peter J Crouch; SinChun Lim; Su Ling Leong; Simon Wilkins; Jessica George; Blaine R Roberts; Chi L L Pham; Xiang Liu; Francis C K Chiu; David M Shackleford; Andrew K Powell; Colin L Masters; Ashley I Bush; Graeme O'Keefe; Janetta G Culvenor; Roberto Cappai; Robert A Cherny; Paul S Donnelly; Andrew F Hill; David I Finkelstein; Kevin J Barnham Journal: J Exp Med Date: 2012-04-02 Impact factor: 14.307
Authors: James S Toomey; Shilpa Bhatia; La'Wanda T Moon; Elysse A Orchard; Kerrie H Tainter; Stephen J Lokitz; Tracee Terry; J Michael Mathis; Andrew D Penman Journal: PLoS One Date: 2012-06-18 Impact factor: 3.240
Authors: Patrick A Randall; Christie A Lee; Eric J Nunes; Samantha E Yohn; Victoria Nowak; Bilal Khan; Priya Shah; Saagar Pandit; V Kiran Vemuri; Alex Makriyannis; Younis Baqi; Christa E Müller; Merce Correa; John D Salamone Journal: PLoS One Date: 2014-06-17 Impact factor: 3.240